Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DASH CAR-T
- Development stage
- Unknown
- Lead developer
- Shanghai HRAIN Biotechnology
- Modality
- Cell Therapies
01
Overview
DASH CAR-T (Shanghai Hrain Biotechnology): sourced facts only. name: "This study introduces an innovative Chimeric Antigen Receptor T (CAR-T) therapy targeting CD276, leveraging our DASH CAR-T manufacturing platform." [DOI:10.1158/1538-7445.am2024-4008]; target: "This study introduces an innovative Chimeric Antigen Receptor T (CAR-T) therapy targeting CD276, leveraging our DASH CAR-T manufacturing platform." [DOI:10.1158/1538-7445.am2024-4008]; developer: "1Shanghai Hrain Biotechnology Co., Ltd., Shanghai, China." [DOI:10.1158/1538-7445.am2024-4008]; modality: "This study introduces an innovative Chimeric Antigen Receptor T (CAR-T) therapy targeting CD276, leveraging our DASH CAR-T manufacturing platform." [DOI:10.1158/1538-7445.am2024-4008]
02
Targets
B7-H3
Beyond the preview
Go deeper on DASH CAR-T.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DASH CAR-T.